In the wake of the success of modern immunotherapy, oncolytic viruses (OVs) are currently
seen as a potential therapeutic option for patients with cancer who do not respond or fail to …

Oncolytic viruses can be usefully integrated into tumour immunotherapies, as they target
multiple steps within the cancer–immunity cycle. Oncolytic viruses directly lyse tumour cells …

Oncolytic viruses (OVs) constitute a new and promising immunotherapeutic approach
toward cancer treatment. This therapy takes advantage of the natural propensity of most …

Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach
in treating hematological malignancies. CAR T-cells represent engineered autologous T …

In view of the advancement in the understanding about the most diverse types of cancer and
consequently a relentless search for a cure and increased survival rates of cancer patients …

Oncolytic viral therapy is a new promising strategy against cancer. Oncolytic viruses (OVs)
can replicate in cancer cells but not in normal cells, leading to lysis of the tumor mass …

Cancer vaccines and oncolytic immunotherapy are promising treatment strategies with
potential to provide greater clinical benefit to patients with advanced-stage cancer. In …

Oncolytic viruses (OVs) infect, multiply, and finally remove tumor cells selectively, causing no
damage to normal cells in the process. Because of their specific features, such as, the ability …

Cancer immunotherapy uses the immune system and its components to mount an anti-tumor
response. During the last decade, it has evolved from a promising therapy option to a robust …

Background As a complement to the clinical development of new anticancer molecules,
innovations in therapeutic vectorization aim at solving issues related to tumor specificity and …